Quince Therapeutics, Inc. 8K

Quince Therapeutics announced Q2 2026 results, completed its acquisition of Orphai Therapeutics alongside a $115 million private placement, and refocused on advancing its LAM-001 pulmonary pipeline with sufficient cash to fund operations through 2028 despite a large acquisition-driven net loss.

On August 14, 2026, Quince Therapeutics, Inc. reported its second quarter 2026 financial results and provided a corporate update highlighting the completion of its stock-for-stock acquisition of Orphai Therapeutics, the concurrent closing of a $115 million private placement with potential for up to an additional $83 million from warrant exercises, and a strategic shift toward a late-stage pulmonary pipeline centered on LAM-001, an inhaled formulation of rapamycin being advanced through multiple Phase 2 studies in PH-ILD, BOS, and SAPH. The company outlined clinical timelines with Phase 2b PH-ILD data expected in Q1 2028, BOS Phase 2 data in Q1 2027, and initiation of a SAPH Phase 2 trial in late 2026 with data expected in Q4 2028, and reported that cash and cash equivalents of $116 million as of June 30, 2026 are expected to fund operations through the end of 2028. Financially, Quince recorded a net loss of $75.5 million for the quarter, driven largely by a $59 million acquired in-process R&D charge and higher G&A expenses related to non-cash stock-based compensation and professional fees tied to the acquisition and restructuring, and disclosed that it had effected two reverse stock splits (1-for-10 on April 10, 2026 and 1-for-20 on June 29, 2026), resulting in 978,022 shares of common stock outstanding as of June 30, 2026.

Filing Facts

CIK

1662774

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-350568

Alert Tier

7